

1 **Microbiota-Short Chain Fatty Acid Relationships Underlie Clinical Heterogeneity and**  
2 **Identify Key Microbial Targets in Irritable Bowel Syndrome (IBS)**

3 <sup>1</sup>Andrea Shin,\* <sup>2</sup>Yue Xing, <sup>3</sup>Mohammed Rayyan Waseem, <sup>3</sup>Robert Siwiec, <sup>3</sup>Toyia James-  
4 Stevenson, <sup>3</sup>Nicholas Rogers, <sup>3</sup>Matthew Bohm, <sup>3</sup>John Wo, <sup>3</sup>Carolyn Lockett, <sup>3</sup>Anita Gupta,  
5 <sup>3</sup>Jhalka Kadariya, <sup>4</sup>Evelyn Toh, <sup>3</sup>Rachel Anderson, <sup>5</sup>Huiping Xu, <sup>2</sup>Xiang Gao\*

6 (\*co-corresponding authors)

7 from the <sup>1</sup>Vatche and Tamar Manoukian Division of Digestive Diseases at the University of  
8 California Los Angeles, Los Angeles, CA; the <sup>2</sup>Department of Medicine at Stritch School of  
9 Medicine, Loyola University Chicago, Chicago, IL; the <sup>3</sup>Division of Gastroenterology and  
10 Hepatology, Indiana University School of Medicine, Indianapolis, IN; the Department of  
11 Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN; and  
12 the <sup>5</sup>Department of Biostatistics and Health Data Science, Indiana University School of  
13 Medicine, Indianapolis, Indiana

14 **Short Title:** Microbiota-SCFA Associations in IBS

15 **Acknowledgements:** The authors would like to thank the Mayo Clinic Department of  
16 Laboratory Medicine and Pathology and Purdue University Metabolite Profiling Facility for their  
17 collaboration and assistance with quantification of stool bile acids and short chain fatty acids.

18 **Word Count:** 5076 excluding abstract, references, table/figure legends).

19 **Funding:** AS has received funding from NIDDK K23DK122015 and R03DK132446.

20 **Abbreviations:** ALR=additive log-ratio; BAM=bile acid malabsorption; CTT=colonic transit  
21 time; gDNA=genomic DNA; GI=gastrointestinal; GLM=generalized linear model; GMM=gut

22 metabolic module; IBS=irritable bowel syndrome; IBS-D=IBS with diarrhea; IBS-C IBS with  
23 constipation; KEGG=Kyoto Encyclopedia of Genes and Genomics; KO=KEGG Orthogroup;  
24 LC-MS=liquid chromatography-mass spectrometry; SCFA=short chain fatty acids

25 **Disclosures:** AS serves on Ardelyx Scientific Communications Advisory Board for irritable  
26 bowel syndrome with constipation.

27 **Author Contributions:** Developing study concept: AS. Planning study design: AS, HX, XG.  
28 Participant recruitment: AS, MRW, RS, TJS, NR, MB JW, CL, AG, JK, RA. Data collection and  
29 study procedures: AS, MRW, CL, AG, JK, ET. Data Management: AS, YX, MRW, CL, JK, HX,  
30 XG. Data Analysis and Interpretation: YX, XG. Drafting the manuscript: AS, XG. Critically  
31 revising the manuscript: MRW, RS, TJS, NR, MB, JW, ET, HX.

32 **Data Transparency Statement:** Microbiome sequencing reads are deposited into NCBI with  
33 accession number SUB13882354. The data that support the findings of this study are available  
34 upon reasonable request from the corresponding author.

35 **Correspondence:**

36 Andrea S. Shin, M.D., M.Sc.; G. Oppenheimer Center for Neurobiology of Stress and  
37 Resilience; David Geffen School of Medicine at UCLA; 10833 Le Conte Avenue, CHS 42-210;  
38 Los Angeles, CA 90095-7378; Tel: (310) 206-0192; Fax: (310) 825-1919

39 Xiang Gao, PhD.; Department of Medicine; Stritch School of Medicine at Loyola University  
40 Chicago; 2160 S. Frist Avenue; Maywood, IL 60153; Tel: (708) 327-9021

41

42 **ABSTRACT**

43 **Background:** Identifying microbial targets in irritable bowel syndrome (IBS) and other  
44 disorders of gut-brain interaction (DGBI) is challenging due to the dynamic nature of  
45 microbiota-metabolite-host interactions. SCFA are key microbial metabolites that modulate  
46 intestinal homeostasis and may influence IBS pathophysiology. We aimed to assess microbial  
47 features associated with short chain fatty acids (SCFA) and determine if features varied across  
48 IBS subtypes and endophenotypes. Among 96 participants who were screened, 71 completed the  
49 study. We conducted in-depth investigations of stool microbial metagenomes, stool SCFA, and  
50 measurable IBS traits (stool bile acids, colonic transit, stool form) in 41 patients with IBS (IBS  
51 with constipation [IBS-C] IBS with diarrhea [IBS-D]) and 17 healthy controls. We used partial  
52 canonical correspondence analyses (pCCA), conditioned on transit, to quantify microbe-SCFA  
53 associations across clinical groups. To explore relationships between microbially-derived SCFA  
54 and IBS traits, we compared gut microbiome-encoded potential for substrate utilization across  
55 groups and within a subset of participants selected by their stool characteristics as well as stool  
56 microbiomes of patients with and without clinical bile acid malabsorption.

57 **Results:** Overall stool microbiome composition and individual taxa abundances differed between  
58 clinical groups. Microbes-SCFA associations differed across groups and revealed key taxa  
59 including *Dorea* sp. CAG:317 and *Bifidobacterium pseudocatenulatum* in IBS-D and  
60 *Akkermansia muciniphila* and *Prevotella copri* in IBS-C that that may drive subtype-specific  
61 microbially-mediated mechanisms. Strongest microbe-SCFA associations were observed in IBS-  
62 D and several SCFA-producing species surprisingly demonstrated inverse correlations with  
63 SCFA. Fewer bacterial taxa were associated with acetate to butyrate ratios in IBS compared to  
64 health. In participants selected by stool form, we demonstrated differential abundances of

65 microbial genes/pathways for SCFA metabolism and degradation of carbohydrates and mucin  
66 across groups. SCFA-producing taxa were reduced in IBS-D patients with BAM.

67 **Conclusion** Keystone taxa responsible for SCFA production differ according to IBS subtype and  
68 traits and the IBS microbiome is characterized by reduced functional redundancy. Differences in  
69 microbial substrate preferences are also linked to bowel functions. Focusing on taxa that drive  
70 SCFA profiles and stool form may be a rational strategy for identifying relevant microbial targets  
71 in IBS and other DGBI.

72 **Key words:** colonic microflora, bile acid metabolism, gut-brain interaction, functional  
73 gastrointestinal disorder, microbiome

74

## 75 INTRODUCTION

76 Irritable bowel syndrome (IBS) is a burdensome disorder of gut-brain interaction with an  
77 estimated global prevalence rate of 5-10%.<sup>1</sup> Pathophysiological mechanisms of IBS include  
78 disturbances in motility or transit, altered intestinal secretion, impaired intestinal permeability,  
79 immune cell reactivity, visceral hypersensitivity, and dysregulated neural signaling and/or central  
80 processing.<sup>2</sup> Despite advancements in the understanding of IBS pathogenesis, diagnostic and  
81 therapeutic IBS biomarkers are limited.

82 Accumulating evidence suggests that the gastrointestinal (GI) microbiome is associated  
83 with risk of IBS and may also mediate many of the mechanisms that underlie symptoms  
84 including altered motility,<sup>3,4</sup> barrier dysfunction,<sup>5</sup> immune activation,<sup>6,7</sup> signaling along the  
85 brain-gut axis,<sup>8</sup> and visceral sensation.<sup>9</sup> Characterization of microbial composition in IBS has  
86 suggested decreased microbial diversity, reduced temporal stability, or changes in the relative  
87 abundance of specific bacteria in patients with IBS.<sup>10,11</sup> However, these findings have not been  
88 sufficiently consistent across studies to establish a clear microbial profile in IBS and gaps in our  
89 understanding of the functional microbiome persist. Integrating complementary strategies in the  
90 investigation of microbial metabolites will be crucial for gathering actionable insights into the  
91 impact of the microbiome in IBS.

92 Atypical profiles of microbial metabolites including luminal bile acids<sup>12,13</sup> and short  
93 chain fatty acids (SCFA) have been described in some patients with IBS.<sup>14,15</sup> Bile acid  
94 malabsorption (BAM) is recognized as a mechanistic IBS subtype that can be assessed through  
95 several diagnostic methods including measurement of total or primary stool bile acids.<sup>13</sup> Studies  
96 have demonstrated BAM to be associated with physiological traits, symptoms, and quality of  
97 life.<sup>16-19</sup> Recently, researchers have examined microbial contributions to BAM in IBS to report

98 alterations such as enrichment of *Clostridia* bacteria including *C. scindens*,<sup>20</sup> lower microbial  
99 alpha diversity, higher Firmicutes to Bacteroidetes ratio,<sup>19</sup> and presence of endoscopically visible  
100 biofilms correlating with overgrowth of *Escherichia coli* and *Ruminococcus gnavus*.<sup>21</sup>

101 SCFA are produced by anaerobic fermentation of dietary fibers and resistant starch that  
102 enter the colon and regulate intestinal homeostasis and physiology.<sup>22</sup> Compared to bile acids, the  
103 role of SCFA in IBS is less well understood. Studies of stool SCFA in IBS have yielded variable  
104 results, which may be related to the heterogeneity of the IBS patient populations and multiple  
105 pathways through which SCFA may modulate intestinal physiology. Therefore, while stool  
106 SCFA are unlikely to serve as categorical IBS biomarkers, they may provide critical insights into  
107 the pathophysiological mechanisms that underlie IBS symptoms or serve as a tool for identifying  
108 metabolically relevant microbial targets. Studies<sup>15, 23</sup> that have assessed stool SCFA in distinct  
109 IBS subgroups have reported more consistent associations of stool SCFA with IBS subtypes as  
110 well as correlations of stool SCFA with measurable IBS traits such as colonic transit, bowel  
111 functions, and bile acid excretion.<sup>23-25</sup> Despite these reports, the intercorrelation between SCFA  
112 and transit time complicates the assessment of whether SCFA profiles represent the metabolic  
113 capacity of the resident microbiome. It remains unclear if studying the relationships between the  
114 microbiome and excreted SCFA is clinically informative. Recent work<sup>26</sup> has suggested that  
115 individual or keystone taxa, rather than complex ecological communities, could drive changes in  
116 SCFA output in response to dietary fiber. Therefore, strategies that isolate major microbial  
117 features (or keystone taxa) that shape luminal SCFA may serve as a rational method for selecting  
118 functionally relevant microbial targets in patients with IBS. To address these questions, we  
119 conducted an in-depth investigation of GI microbiome composition and function, stool SCFA,

120 and IBS endophenotypes defined according to quantitative traits (transit, bile acids, bowel  
121 functions) in adults with and without IBS.

## 122 **MATERIALS AND METHODS**

123 *Participant Recruitment and Study Design:* The study was approved by the Indiana University  
124 Institutional Review Board and the protocol registered within ClinicalTrials.gov  
125 (NCT02981888). The study was designed as an observational investigation of stool SCFA, stool  
126 bile acids, colonic transit, and stool microbiota in adults with and without IBS. We enrolled  
127 adults ages 18-65 years of age through the Indiana University Gastroenterology Clinics, the  
128 Indiana Clinical and Translational Research Institute Research Registry, and from the local  
129 community. We included individuals with IBS with diarrhea (IBS-D) or IBS with constipation  
130 (IBS-C) according to Rome IV criteria<sup>27</sup> and healthy controls with no prior history of GI diseases  
131 or symptoms. Detailed eligibility criteria are available in the Supplemental Methods.

132 *Data Collection:* Study eligibility, medications, medical history, and baseline diet using a food  
133 frequency questionnaire<sup>28</sup> were assessed during a screening visit with a study physician. Over a  
134 two-week period, data were collected on bowel functions using a standardized bowel pattern  
135 diary including the Bristol stool form scale.<sup>29</sup> All participants submitted a 48-hour stool  
136 collection collected during the last 2 days of a 4-day 100 g fat diet, consistent with clinically  
137 validated methods for identifying BAM. Specimens were refrigerated during the collection  
138 period, returned to the research team on ice, and stored at -80°C.

139 *Colonic Transit by Radiopaque Markers:* Participants underwent assessment of colonic transit  
140 time with a previously validated and optimized method using radiopaque markers.<sup>30</sup>

141 *Stool SCFA and Bile Acids:* Frozen aliquots of stool were shipped to the Metabolite Profiling  
142 Facility at Purdue University to measure total and individual SCFA concentrations per mg of dry  
143 weight by liquid chromatography-mass spectrometry (LC-MS) using published methods<sup>31</sup> and to  
144 the Mayo Clinic Department of Laboratory Medicine and Pathology to measure total and  
145 primary stool bile acid levels by high-performance LC-MS through a commercially available,  
146 CLIA-approved assay.<sup>16, 32, 33</sup> Individual SCFA of interest included acetate, butyrate, and  
147 propionate as these represent the predominant SCFA produced in humans.<sup>34</sup>

148 *DNA Extraction, Purification, and Sequencing:* Genomic DNA was isolated from stool using the  
149 QIAmp® PowerFecal® DNA kit (QIAGEN Inc., Germantown, MD, USA). DNA quality and  
150 concentration were on a Qubit fluorometer. Purified DNA underwent library preparation  
151 (Nextera XT, Illumina) and paired-end (2x150 bp) sequencing using the NovaSeq v1.5 SP  
152 (Illumina, San Diego, CA, USA) to target a sequencing depth of 40M sequences per sample.

153 *Metagenomic Data Analysis:* Metagenomic sequencing reads were quality filtered and processed  
154 for taxonomic profiling using MetaPhlan3. Additive log-ratio (ALR) transformation was applied  
155 to analyze differential taxonomic abundances. Based on the identified microbial taxa from each  
156 sample,  $\beta$ -diversity indices (e.g., Bray-Curtis dissimilarity) were calculated using the R packages  
157 phyloseq and vegan.<sup>35, 36</sup> Functional profiling was conducted using the HUMAnN3 pipeline  
158 annotated by KEGG (Kyoto Encyclopedia of Genes and Genomes) orthogroups (KO).

159 *Statistical Considerations:* We summarized major endpoints of interest: (1) stool microbiome  
160 composition, (2) stool SCFA concentrations (total, acetate, propionate, butyrate), total and  
161 percent primary stool bile acids, and (3) colonic transit time (overall and segmental). Our  
162 primary objective was to quantify the association between microbiome composition and SCFA



163 (microbe-SCFA associations) across clinical groups after controlling for transit and to account  
164 for the mechanistic heterogeneity that underlies clinical IBS populations.

165 We compared microbial taxa abundances between groups and analyzed associations of  
166 taxa abundances with IBS endophenotypes/traits (stool SCFA, stool bile acids, and transit) for  
167 the collective cohort and within groups. Associations of microbiome composition with group  
168 were assessed using general linear regression models (GLM) adjusted for covariates including  
169 age, sex, and BMI. Only high abundant species (relative abundance  $\geq 0.1\%$ ) that were prevalent  
170 in  $\geq 2$  specimens within  $\geq 1$  clinical group were considered. Partial Canonical Correspondence  
171 Analysis (pCCA) conditioned on transit time was employed to quantify the relationship between  
172 the microbiome and stool SCFA in all participants and within clinical groups, using the vegan  
173 package in R. The significance of the model was assessed through a permutation test with 999  
174 iterations. To identify bacteria whose abundances were strongly associated with the stool SCFA  
175 concentrations, we focused on those bacteria scattered along the direction of specific SCFA axis  
176 in the biplot, within a 60-degree angle centered around the SCFA axis in both positive and  
177 negative directions. The strength of association between the bacteria and the SCFA was ranked  
178 by projecting of the bacteria species scores onto each SCFA axis in the biplot. Bacteria with  
179 projection scores less than 0.5 were excluded from the subsequent analysis.

180 For exploratory analyses, we analyzed multivariable associations of microbiome  
181 composition with clinical BAM among individuals with IBS-D. Relative abundances were used  
182 to examine the associations of gene family/pathway abundances across clinical groups. A  
183 manually curated gut-metabolic analysis framework<sup>37</sup> was applied to examine KO identifiers  
184 associated with carbohydrate degradation, SCFA production or metabolism, and mucin  
185 degradation using GLM adjusting for covariates. As stool form<sup>38</sup> has been identified as a strong

186 source of human microbiota variation and closely linked to transit,<sup>39, 40</sup> we further explored  
187 associations of functional potential across groups in a subset of participants who were selected  
188 based on stool form features (i.e. those individuals best representing the stool types within their  
189 respective clinical group according to bowel diary data) using the Kruskal-Wallis test. For  
190 example, we chose the IBS-D and IBS-C participants with the loosest and firmest stool types,  
191 respectively, and controls with consistently normal stool types. For all endpoints, missing values  
192 were excluded from the analysis for that endpoint.

## 193 **RESULTS**

194 *Participant Characteristics:* Among 96 volunteers who underwent screening evaluation, 71  
195 completed the study, and 58 participants (Figure 1) with a mean [ $\pm$ SD] age = 35.5 ( $\pm$ 13.8) years  
196 and mean [ $\pm$ SD] BMI = 26.2 [ $\pm$ 7.5] kg/m<sup>2</sup>) were included in the final analysis after excluding  
197 those who ineligible (n=16), lost to follow-up (n=9), or and/or did not provide SCFA data  
198 (n=13). Baseline clinical characteristics (Table 1) were not significantly different across groups  
199 (all p=ns). Comparisons of quantitative traits demonstrated differences in total stool bile acids  
200 and transit between IBS-D and control participants and in total stool SCFA and stool acetate)  
201 between IBS and controls Table 2, Figures 2-3.

### 202 *Stool microbiome composition differs between IBS and health and between IBS subtypes:*

203 Shotgun metagenomic sequencing of stool samples was undertaken to obtain total of 3.1 Gb of  
204 sequence data after removal of contaminants with an average of 37.6 million paired-end reads  
205 per sample (deposited into NCBI with accession number SUB13882354). Taxonomic  
206 classification identified 461 taxa at species level classification. Comparisons of microbial  
207 metagenomes based on Bray-Curtis Dissimilarity revealed significant divergence (Supplemental  
208 Figure 1) of community distance between groups (p=0.003, R<sup>2</sup> =0.06) after adjusting for age,

209 BMI, and diet. We compared abundances of individual taxa across groups using the Kruskal-  
210 Wallis test to identify 18 unique and differentially abundant taxa. Highest mean relative  
211 abundances of 14 taxa (Supplemental Table 1) including *Dorea* sp. CAG:317, *Blautia* sp.  
212 CAG:257, *Ruminococcus gnavus*, and *Proteobacteria* bacterium CAG:139 were observed in  
213 IBS-D, which have previously been linked to mechanisms such as BAM<sup>20, 21</sup> and serotonin  
214 biosynthesis in patients with IBS-D.<sup>41</sup> *Lawsonibacter asaccharolyticus* abundance was highest in  
215 IBS-C and *Firmicutes* bacterium CAG:83 abundance was highest in controls.

216 We followed unadjusted analyses with pairwise comparisons of ALR-transformed taxa  
217 abundances using covariate-adjusted GLM, focusing on high abundant species, to demonstrate  
218 significant differences in 17 pairwise comparisons including 12 unique species (Figure 4) of  
219 which 11 exhibited differential abundances of  $\geq 3$ -fold. Among these taxa, we observed  
220 significantly higher abundances of *Dorea* sp. CAG:317 and *Bifidobacterium pseudocatenulatum*  
221 in IBS-D compared to IBS-C or controls and higher abundances of *Blautia* sp. CAG:257, and  
222 *Proteobacteria* bacterium CAG:139 in IBS-D compared to controls. We found significantly  
223 higher abundances of *Clostridium* sp. CAG:58 and lower abundances of *Firmicutes* bacterium  
224 CAG:83 in both IBS-D and IBS-C relative to controls, respectively. *Akkermansia muciniphila*  
225 and *Prevotella copri* were increased in IBS-C compared to controls. Differences of  $\geq 3$ -fold in  
226 relative abundances among high abundant bacteria were also observed in 151 pairwise  
227 comparisons (Supplemental Table 2) but were not statistically significant after adjustment for  
228 covariates.

229 *Microbe-SCFA associations differ between IBS subtypes and controls:* We conducted pCCA on  
230 microbiome and SCFA data, conditioned on transit time, to quantify relationships between taxa  
231 abundances and stool SCFA in the overall cohort and within clinical groups. In the overall

232 cohort, we observed a significant correlation between microbiome abundance matrix and SCFA  
233 concentration matrix ( $p=0.033$ ,  $R^2 = 0.095$ ). Relationships between microbiome abundances and  
234 SCFA concentrations within clinical groups (Supplemental Figure 2) were more pronounced  
235 within IBS-D ( $p=0.015$ ) and less pronounced in HV and IBS-C ( $p=ns$ ). In the overall cohort,  
236 strongest positive associations with total SCFA were observed with *Bacteroides plebeius*,  
237 *Prevotella sp. CAG:1031*, and *Bifidobacterium pseudocatenulatum*.

238 Distinct taxa correlate with individual SCFA across clinical subgroups: Keeping in mind that  
239 SCFA effects may depend on SCFA type, we ranked bacterial taxa according to their projection  
240 scores for individual SCFAs to assess the pattern of associations between bacterial species and  
241 SCFA profiles. Bacteria with higher projection scores for individual SCFAs were considered to  
242 have stronger associations with those specific SCFAs. Bacteria with projection scores less than  
243 0.5 were excluded from the subsequent analysis. In general, the strength and direction of  
244 correlations of individual taxa with acetate, butyrate, and propionate differed according to  
245 clinical group (Figure 5). No microbes demonstrated consistent patterns of strong correlations  
246 with individual SCFA across all three groups. The greatest number of bacteria with strong  
247 associations with SCFA were observed in IBS-D, as evidenced by the larger number of bacteria  
248 remaining in the ranked list after filtering. Most microbe-SCFA patterns differed between IBS-D  
249 and IBS-C and only a few bacterial species including *Ruminococcus torques*, *Coprococcus*  
250 *comes*, *Clostridium sp. CAG:299*, *Bacteroides eggerthii*, and *Adlercreutzia equolifaciens*  
251 demonstrated consistent associations across both IBS subtypes with acetate and butyrate.

252 In IBS-D, both positive and negative correlations with stool acetate were observed with  
253 multiple taxa. Largest negative projections were observed with several bacteria that have  
254 previously linked to SCFA production (*B. plebeius*, *Roseburia hominis*),<sup>42, 43</sup> dietary

255 polysaccharides and protein utilizers (*Firmicutes* bacterium CAG:110),<sup>44</sup> starch or  
256 fructooligosaccharide degradation (*Bifidobacterium adolescentis*), fiber fermentation (e.g.  
257 *Clostridium leptum*<sup>45</sup>),  $\beta$ -fructan utilizers (e.g. *Roseburia inulinivorans*).<sup>45</sup> Positive projections  
258 were observed with *Dialister* sp. CAG 357, *B. pseudocatenulatum*, *Alistipes* species, *Prevotella*  
259 sp. CAG:1031, *R. toques*, and *R. gnavus*. In IBS-C, largest negative projections for acetate were  
260 observed between abundances of *Dorea* sp. CAG:317, *Lachnospira pectinoschiza*, and  
261 *Prevotella* sp. CAG:1031 while the largest positive projections were observed with  
262 *Streptococcus salivarius*, *Bacteroides fragilis*, and *R. torques*. In controls, largest negative  
263 projections for acetate were observed with *B. plebeius*, *Dialister* sp. CAG:357, *Bacteroides*  
264 *dorei*, and *A. muciniphila*. The largest positive projection for acetate among controls was  
265 observed with *Ruminococcus lactaris*.

266 Analysis of microbe-butyrate associations in IBS-D demonstrated negative projection  
267 scores for butyrate with several bacteria including *Ruminococcaceae* bacterium D5, *Firmicutes*  
268 bacterium CAG:110, *C. leptum*, *R. hominis*, *R. inulinivorans*, and *L. asaccharolyticus*. The  
269 largest positive projection scores for butyrate were observed with *Alistipes* species, *Prevotella*  
270 sp. CAG:1031, and *R. torques*. In IBS-C and controls, patterns of microbe-butyrate associations  
271 largely mirrored the patterns of microbe-acetate associations observed within the respective  
272 clinical groups. In addition, a positive relationship between butyrate and *Bacteroides*  
273 *thetaiotaomicron*, a well-known human commensal<sup>46, 47</sup> that exhibits the capacity to digest a  
274 broad array of polysaccharides and host glycans, was also observed in IBS-C.

275 For propionate, most microbes including *Ruminococcaceae* bacterium D5, *Firmicutes*  
276 bacterium CAG:110, *C. leptum*, *L. asaccharolyticus*, *Ruthenibacterium lactatiformans* and  
277 *Bacteroides massiliensis* exhibited negative associations in IBS-D with only a few exceptions

278 including *S. salivarius*, for which the largest positive correlation was observed. In contrast, both  
279 positive and negative projections for stool propionate were observed in IBS-C; the largest  
280 positive scores were observed for *Paraprevotella xylaniphila*, *Phascolarctobacterium*  
281 *succinatutens*, and *P. copri*. Among controls, both positive and negative associations with  
282 propionate were observed for multiple bacterial taxa.

283 Lower number of bacterial species associated with acetate to butyrate ratios in IBS: Since  
284 interconversion of SCFA from acetate to butyrate may represent a major route of butyrate  
285 formation within the gastrointestinal tract,<sup>48</sup> we examined bacterial relationships with acetate to  
286 butyrate ratios to identify top taxa associated the metabolic processes that drive SCFA output.  
287 The largest positive associations were observed with *Prevotella* sp. 885, *Firmicutes* bacterium  
288 CAG:83, *P. xylaniphila* in IBS-D, suggesting that these species were associated with shift toward  
289 decreased butyrate production. Unlike the patterns observed with individual SCFA, analysis  
290 acetate to butyrate ratios demonstrated that the number of ranked bacteria were substantially  
291 lower in IBS-D or IBS-C compared to controls (Figure 5), suggesting the possibility of reduced  
292 functional redundancy for butyrate formation in IBS.

293 Reduced SCFA-producing microbes and bile acid malabsorption (BAM): Stool microbial  
294 metagenomes were analyzed in 22 IBS-D patients with (n=8) and without (n=14) clinical BAM  
295 according to previously validated diagnostic cutoff values.<sup>12, 13</sup> Comparisons of beta diversity  
296 based on Euclidian dissimilarity of ALR transformed abundance data showed significant  
297 dissimilarity ( $p = 0.039$ ;  $R^2 = 0.061$ ) between patients with and without BAM (Supplemental  
298 Figure 3). Significant differences in six high abundant species were observed between groups,  
299 including *L. asaccharolyticus* *R. inulinivorans*, *L. pectinoschiza*, and *F. saccharivorans* which

300 were also associated with stool SCFA, but not bile acids, in IBS-D. These four species with  
301 known SCFA-producing capacity were negatively correlated with BAM.

302 *Functional potential for carbohydrate degradation, SCFA metabolism, and mucin degradation:*

303 Examination of microbial gene families and pathways yielded 949,223 total gene families within  
304 the metagenome data set including 4,042 named KO terms. We applied a gut metabolic module  
305 (GMM) framework to analyze modules related to carbohydrate degradation, SCFA production or  
306 metabolism including bacterial cross-feeding pathways, mucin degradation, and one module  
307 related to serine degradation based on significant species-based predictors. Abundances of KO  
308 identifiers within modules for lactose degradation, ( $p=0.0026$ ), serine degradation ( $p=0.019$ ), and  
309 propionate production ( $p=0.026$ ) were significantly enriched in IBS-C compared to controls.  
310 Relative abundance of a KO identifier within a galactose degradation module was significantly  
311 reduced in IBS-D ( $p=0.033$ ) compared to controls. In the collective cohort, we applied the GMM  
312 framework to analyze the relationships between metagenomically-encoded functions and stool  
313 SCFA. We identified 23, 23, 15, and 16 KO identifiers from relevant GMMs that were  
314 significantly associated with total SCFA, acetate, butyrate, and propionate, respectively. Within a  
315 representative subset ( $n=6$  controls,  $n=5$  IBS-D,  $n=5$  IBS-C) selected by stool form  
316 characteristics, functional metagenomic analyses demonstrated that microbial genes/pathways  
317 associated with SCFA production/metabolism and degradation of carbohydrates/ mucin were  
318 differentially associated with clinical group (Figure 6).

319 **DISCUSSION**

320 It has been proposed that changes in intestinal SCFAs in some patients with IBS are  
321 caused by shifts in microbial composition and function to drive and maintain symptoms. We  
322 hypothesized that specific features of the GI microbiome may correlate with SCFA output and

323 that these relationships may distinguish IBS subtypes and endophenotypes. We further  
324 hypothesized that functional features of the GI microbiome defined by substrate preferences and  
325 SCFA metabolism may be linked to bowel dysfunction. Using a dual-omics approach, our  
326 findings demonstrate microbiota-SCFA relationships differ between IBS subtypes and  
327 endophenotypes, and between patients with IBS and healthy controls. We elected to focus on  
328 microbe-SCFA relationship due to the established biological relevance of SCFA in GI  
329 physiology and to use a focused strategy for identifying the microbes involved in shaping the  
330 microbial metabolome. Our findings suggest that key taxa may predict IBS mechanisms and that  
331 the functional repertoire of the intestinal microbiome influences bowel functions. By capturing  
332 quantifiable traits, we also gather evidence suggesting the microbiome has direct effects on  
333 excreted SCFA and were able to identify microbe-SCFA relationships that are not explained by  
334 transit, to potentially isolate major microbial features (or keystone taxa) that shape SCFA output.

335 While numerous studies have reported compositional changes<sup>11</sup> in IBS such as decreased  
336 microbial diversity and altered abundances of individual taxa, consistent patterns are difficult to  
337 pinpoint and limit our ability to draw actionable insights. Recent data suggest that putative  
338 microbial biomarkers are related to mechanistic and host-specific features in IBS rather than the  
339 overall clinical syndrome. Consistent with these prior studies, we observed differences in overall  
340 microbial community composition across groups. Comparisons of taxa abundances demonstrated  
341 significant changes were most common in IBS-D and predominantly characterized by higher  
342 abundances of several bacterial species including *Blautia* sp. CAG:257, *R. gnavus*, *Dorea* sp.  
343 CAG:317, and *Proteobacteria* bacterium CAG:139. *R. gnavus*, a Lachnospiraceae, has  
344 previously been identified to play a pathogenic role in IBS-D through serotonin biosynthesis,<sup>41</sup>  
345 biofilm formation and increased stool bile acid excretion,<sup>21</sup> production of proinflammatory



346 polysaccharides,<sup>49</sup> and mucin degradation.<sup>50</sup> Interestingly, the relationship between *R. gnavus*  
347 and IBS lost its significant in adjusted analyses due to a positive association between *R. gnavus*  
348 and BMI which may suggest a role *R. gnavus* in explaining the connection between IBS-D or  
349 chronic diarrhea with metabolic syndrome and obesity-related disorders although further  
350 validation of this hypothesis will be required.<sup>51</sup> Associations of IBS-D with other taxa including  
351 *Dorea* sp. CAG:317, *Blautia* sp. CAG:257, and *Proteobacteria* bacterium CAG:139 remained  
352 and a new association between *B. pseudocatenulatum* and IBS-D emerged. In our analyses of  
353 microbe-SCFA relationships, strongest contributions to SCFA in the overall cohort were  
354 observed with *Bacteroides plebeius*, *Prevotella* sp. CAG:1031, and *B. pseudocatenulatum*  
355 suggesting these taxa as major drivers of microbial metabolism which is consistent with their  
356 known functions. *B. plebeius* harbors a specialized polysaccharide utilization locus acquired  
357 through horizontal gene transfer from marine bacteria.<sup>52, 53</sup> *Prevotella* spp. are highly prevalent  
358 within the human gut, and is largely regarded as a fiber degrader that is associated with agrarian  
359 or plant-based diets, although strain-level variations may impact their contributions to health and  
360 disease.<sup>54</sup> *B. pseudocatenulatum* is recognized as an adult-type *Bifidobacterium* that is  
361 metabolically adapted toward dietary carbohydrates including long-chain xylans.<sup>55</sup> Among the  
362 three clinical groups, we found microbe-SCFA associations were most pronounced in IBS-D and  
363 that fewer microbes were linked to acetate and butyrate ratios. These observations may indicate  
364 that microbial contributions to SCFA profiles are particularly important in IBS-D and may also  
365 imply a greater degree of microbial specialization and reduced functional redundancy.  
366 Previously, Jacobs et al.<sup>56</sup> reported significant increases in transcript abundances for  
367 fructooligosaccharide and polyol utilization and upregulation of transcripts for fructose and  
368 glucan metabolism as well as the succinate pathway for carbohydrate fermentation in IBS.

369 Comparisons between IBS-D and IBS-C demonstrated differences in microbial metabolism with  
370 upregulation of multiple metabolic pathways including transcripts for fructose, mannose, and  
371 polyol metabolism in IBS-D. Together, our findings suggest that differences microbial  
372 metabolism between IBS subtypes may underlie variations in clinical symptoms or that changes  
373 in microbial metabolism could play a particularly prominent role in IBS-D. These findings could  
374 explain the higher prevalence of mixed- and diarrhea-predominant symptoms in post-infection  
375 IBS<sup>57, 58</sup> as well as the limited evidence for efficacy of antimicrobial treatments such as rifaximin  
376 in IBS-C<sup>59</sup> relative to IBS-D.<sup>60, 61</sup>

377 *Dorea* sp. CAG:317 and *B. pseudocatenulatum* were identified as top ranked bacteria  
378 associated with acetate to butyrate ratio and acetate concentrations. Mucin degradation has been  
379 described among several *Dorea* species and the genus *Dorea* belongs to the Lachnospiraceae  
380 family, a major producer of SCFA,<sup>62</sup> Notably, Wang et al.<sup>63</sup> recently demonstrated that while  
381 xylan supplementation following fiber deprivation alleviated gut dysbiosis through selective  
382 promotion of *B. pseudocatenulatum*, these changes were found to be associated with lower  
383 community diversity. *Dorea* sp. CAG:317 and *B. pseudocatenulatum* may represent keystone  
384 taxa linked to altered microbial metabolism or persistent impairment in community recovery  
385 among patients with IBS-D. Only two bacterial species, *A. muciniphila* and *P. copri* were  
386 significantly increased in IBS-C. Although relationships between microbes and SCFA were less  
387 clear in IBS-C. *P. copri* was further identified as top ranked bacteria that was positively  
388 associated with propionate and negatively associated with acetate to butyrate ratio in IBS-C.  
389 Previous studies have reported increased *A. muciniphila* in IBS-C to be protective against  
390 experimentally-induced colitis in mice<sup>64</sup> and a positive association between mucosal *P. copri*  
391 abundance and abdominal pain in patients with IBS without prior history of infection.<sup>65</sup> Others

392 have demonstrated that IBS patients with high levels of propionate present with worse  
393 gastrointestinal symptoms, quality of life, and negative emotions.<sup>15</sup> *P. copri* is a prominent gut  
394 commensal that contributes to propionate production via the succinate pathway<sup>66</sup> and has been  
395 linked to both beneficial and harmful effects on human health. Rolhion et al. found *P. copri* to be  
396 associated with mucus erosion and increased propionate. In another study by Jiang et. al, *P. copri*  
397 colonization was associated with proinflammatory effects following a a high fiber diet in patients  
398 with rheumatoid arthritis through succinate production.<sup>67</sup> Exacerbation of rheumatoid with the  
399 high fiber diet in the presence of *P. copri* colonization led to microbial dysbiosis characterized  
400 by increased abundance of *Akkermansia*, which was also increased in our own IBS-C cohort.

401 In addition to identify major microbial features associated with individual SCFA, we  
402 made several important observations related to the pattern or direction of observed microbe-  
403 SCFA relationships. Interestingly, negative correlations were observed in the IBS-D subgroup  
404 between several SCFA-producing species including *R. hominis*, *B. adolescentis*, *R. inulinivorans*  
405 and individual SCFA. *B. adolescentis* utilizes fructo-oligosaccharides and starch and leads to the  
406 production of lactate and acetate which is cross-fed to butyrate-producing anaerobes,<sup>68</sup> but have  
407 also been identified as a potential GABA producer and correlated with anxiety and/or  
408 depression,<sup>69</sup> which are common comorbid conditions in patients with IBS. *R. inulinivorans* is a  
409 known fiber fermenter<sup>45</sup> that also possesses the ability to forage mucin through a metabolic  
410 interplay with other members of the intestinal microbiota<sup>70</sup> and is also known for net acetate  
411 uptake,<sup>66</sup> which may explain its correlation with reduced SCFA. In general, analysis of bacterial  
412 associations with individual SCFAs demonstrated the largest number of negative associations in  
413 IBS-D. Many of these negative correlations involved bacterial species that have been implicated  
414 in SCFA production and polysaccharide utilization. Findings may imply disrupted cross-feeding

415 mechanisms, modifications in substrate utilization, competitive inhibition, or other context-  
416 specific changes leading to altered microbial metabolism in IBS. Upon analyzing relationships of  
417 bacterial species with acetate to butyrate ratios, which we studied as a marker for overall SCFA  
418 production and intestinal SCFA availability,<sup>71</sup> we identified fewer top ranked bacteria in IBS  
419 compared to healthy controls to suggest a reduction in overall functional redundancy within the  
420 IBS microbiome. Future work should investigate the effects of bacterial cross-feeding, microbial  
421 conversions, and interactions of the colonic microbiome with diet- and host-derived substrates  
422 that may destabilize the microbiota-mucosal interface to expose vulnerabilities and promote  
423 pathophysiological mechanisms that drive IBS.

424 A few bacterial species were associated with SCFA in both IBS subtypes including *R.*  
425 *torques*, *C. comes*, *Clostridium* sp. CAG:299, *B. eggerthii*, and *Adlercreutzia equolifaciens*  
426 which may suggest these bacterial species represent shared microbial features across IBS  
427 subtypes. *R. torques* is a mucin-degrading bacteria that has previously been associated with  
428 IBS<sup>72</sup> as well as depression.<sup>73</sup> Similarly, recent studies have demonstrated associations between  
429 *C. comes*<sup>74</sup> and *B. eggerthii*<sup>75</sup> depression and PTSD, which have both been described as  
430 comorbid conditions in IBS. *R. A. equolifaciens* has been described as an anti-inflammatory  
431 commensal in non-alcoholic fatty liver disease.<sup>76</sup> These data could point towards shared  
432 microbial features as novel biomarker of common pathogenic mechanisms in IBS involving the  
433 microbiota-gut-brain axis, possibly through the effects of microbially-derived SCFA.

434 In our comparisons across IBS-D patients by with and without BAM, we observed BAM  
435 to be associated with reduced abundances of several SCFA-producing bacterial species. Similar  
436 observations have been made in studies linking biofilm formation to bile acid accumulation and  
437 reduced SCFA-producing bacteria.<sup>21</sup> Results suggest that BAM exerts indirect effects on the

438 intestinal metabolome or the overall metabolic potential of the colonic microbiota characterized  
439 by a decline in SCFA-producing capacity. We also assessed of functional variations in the GI  
440 microbiome to reveal differential abundances of KO identifiers belonging to metabolic processes  
441 related to degradation of carbohydrates and serine as well as SCFA production. In a subset of  
442 participants selected by stool form characteristics, we identified changes in substrate degradation  
443 potential and fermentative capacity between IBS and controls and between IBS subtypes that  
444 were characterized by increased capacity for starch degradation in controls, enhancement of  
445 distinct mucin-degrading functions in IBS-D vs. IBS-C, and reduced pectin degrading potential  
446 in IBS-C. Results suggest that abnormal stool form in IBS is influenced by microbiota-encoded  
447 substrate preferences.

448         Collectively, our findings indicate there are distinct changes in microbiome composition  
449 may underlie clinical heterogeneity in IBS. Using a dual-omics approach, we demonstrate that  
450 the gut microbiota in IBS-D is characterized by increased metabolic activity, reduced functional  
451 redundancy, and persistently reduced diversity. Several taxa including *R. gnavus*, *Dorea* sp.  
452 CAG:317 and *B. pseudocatenuatum* are identified as the leading candidates for further study as  
453 potential microbial targets in IBS-D. A few unique microbial features including *P. copri*-  
454 associated propionate production and *Akkermansia* expansion may play a crucial role in IBS-C.  
455 Meanwhile, microbial features that are common between subtypes may offer insights into shared  
456 pathophysiological mechanisms involving the microbiota-gut-brain axis in IBS. Identifying the  
457 major microbial features (taxa or functions) that drive metabolic output may be crucial in  
458 defining rational approaches to modulate the microbiome in IBS.

459         Despite study strengths, we recognize the limitations of this work including cross-  
460 sectional sampling, which overlooks the fluctuating nature of the microbiome. To address this,

461 we assessed relationships between microbial abundances and quantifiable IBS endophenotypes  
462 that were defined at the time of specimen collection while accounting for baseline covariates. All  
463 participants were instructed to consume a 4-day high fat diet while otherwise maintaining their  
464 usual diet. Previously, we examined the effect of both habitual diet and real-time intake on  
465 excreted stool SCFA to find that that modest variations in macronutrient intake including  
466 polysaccharides did not exert substantial effects on excreted SCFA.<sup>25, 77</sup> We enrolled patients  
467 with opposing IBS phenotypes from both the university clinics and the surrounding communities  
468 to increase our ability to detect differences between clinical cohorts and limit referral bias. We  
469 also acknowledge that causal microbial mechanisms cannot be determined through the current  
470 work. However, we applied a dual-omics approach to investigate biologically relevant changes in  
471 intestinal microbiome composition and function. Finally, we cannot discount the possibility we  
472 may have missed significant taxa due to the moderate sample size and a risk for Type I errors as  
473 we did not adjust for false discovery rate in our analysis of taxonomic differences. However, our  
474 analytic approach was based on endpoints that were determined *a priori* and we applied a  
475 conservative strategy by focusing on taxa that were associated with SCFA while accounting for  
476 transit. We further limited analyses to high abundant taxa and to species that exhibited >3-fold  
477 change in abundance while focusing on the biological plausibility of our results. Findings from  
478 this study should be validated in larger, longitudinal cohorts, but provide a framework that may  
479 be used to define key microbial interactions and targets in IBS.

480         In conclusion, main findings from this study highlight microbiota-SCFA patterns vary  
481 across clinical IBS phenotypes and endophenotypes. Our observations suggest that a paired  
482 microbe-metabolite approach may represent a viable strategy for identifying actionable microbial  
483 features in heterogenous patient populations. Prominent shifts in microbial composition are

484 observed in IBS-D. These changes appear to affect metabolic capacity, substrate preferences, and  
485 metabolite profiles. In addition, altered microbial substrate uptake may impact stool form or  
486 bowel function in IBS. These findings generate new hypotheses regarding candidate microbes  
487 that could be pursued as actionable microbial biomarkers or metabolically influential features in  
488 the effort to develop rational microbiota-based therapies in IBS.

489

490 **References:**

- 491 1. Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide Prevalence and Burden of  
492 Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study.  
493 *Gastroenterology* 2021;160:99-114 e3.
- 494 2. Ford AC, Sperber AD, Corsetti M, Camilleri M. Irritable bowel syndrome. *Lancet*  
495 2020;396:1675-1688.
- 496 3. Tap J, Derrien M, Tornblom H, et al. Identification of an Intestinal Microbiota Signature  
497 Associated With Severity of Irritable Bowel Syndrome. *Gastroenterology* 2017;152:111-  
498 123 e8.
- 499 4. Anitha M, Vijay-Kumar M, Sitaraman SV, et al. Gut microbial products regulate murine  
500 gastrointestinal motility via Toll-like receptor 4 signaling. *Gastroenterology*  
501 2012;143:1006-16 e4.
- 502 5. Heitkemper MM, Cain KC, Shulman RJ, et al. Stool and urine trefoil factor 3 levels:  
503 associations with symptoms, intestinal permeability, and microbial diversity in irritable  
504 bowel syndrome. *Benef Microbes* 2018;9:345-355.
- 505 6. Sundin J, Rangel I, Repsilber D, Brummer RJ. Cytokine Response after Stimulation with  
506 Key Commensal Bacteria Differ in Post-Infectious Irritable Bowel Syndrome (PI-IBS)  
507 Patients Compared to Healthy Controls. *PLoS One* 2015;10:e0134836.
- 508 7. McCracken VJ, Lorenz RG. The gastrointestinal ecosystem: a precarious alliance among  
509 epithelium, immunity and microbiota. *Cell Microbiol* 2001;3:1-11.
- 510 8. Liu Y, Zhang L, Wang X, et al. Similar Fecal Microbiota Signatures in Patients With  
511 Diarrhea-Predominant Irritable Bowel Syndrome and Patients With Depression. *Clin*  
512 *Gastroenterol Hepatol* 2016;14:1602-1611 e5.



- 513 9. Crouzet L, Gaultier E, Del'Homme C, et al. The hypersensitivity to colonic distension of  
514 IBS patients can be transferred to rats through their fecal microbiota. *Neurogastroenterol*  
515 *Motil* 2013;25:e272-82.
- 516 10. Mars RAT, Frith M, Kashyap PC. Functional Gastrointestinal Disorders and the  
517 Microbiome-What Is the Best Strategy for Moving Microbiome-based Therapies for  
518 Functional Gastrointestinal Disorders into the Clinic? *Gastroenterology* 2021;160:538-  
519 555.
- 520 11. Pittayanon R, Lau JT, Yuan Y, et al. Gut Microbiota in Patients With Irritable Bowel  
521 Syndrome-A Systematic Review. *Gastroenterology* 2019;157:97-108.
- 522 12. Shin A, Camilleri M, Vijayvargiya P, et al. Bowel functions, fecal unconjugated primary  
523 and secondary bile acids, and colonic transit in patients with irritable bowel syndrome.  
524 *Clin Gastroenterol Hepatol* 2013;11:1270-1275 e1.
- 525 13. Vijayvargiya P, Camilleri M, Burton D, et al. Bile and fat excretion are biomarkers of  
526 clinically significant diarrhoea and constipation in irritable bowel syndrome. *Aliment*  
527 *Pharmacol Ther* 2019;49:744-758.
- 528 14. Mars RAT, Yang Y, Ward T, et al. Longitudinal Multi-omics Reveals Subset-Specific  
529 Mechanisms Underlying Irritable Bowel Syndrome. *Cell* 2020;182:1460-1473 e17.
- 530 15. Tana C, Umesaki Y, Imaoka A, et al. Altered profiles of intestinal microbiota and organic  
531 acids may be the origin of symptoms in irritable bowel syndrome. *Neurogastroenterol*  
532 *Motil* 2010;22:512-9, e114-5.
- 533 16. Vijayvargiya P, Camilleri M, Chedid V, et al. Analysis of Fecal Primary Bile Acids  
534 Detects Increased Stool Weight and Colonic Transit in Patients With Chronic Functional  
535 Diarrhea. *Clin Gastroenterol Hepatol* 2019;17:922-929 e2.

- 536 17. BouSaba J, Sannaa W, McKinzie S, et al. Impact of Bile Acid Diarrhea in Patients With  
537 Diarrhea-Predominant Irritable Bowel Syndrome on Symptoms and Quality of Life. *Clin*  
538 *Gastroenterol Hepatol* 2022;20:2083-2090 e1.
- 539 18. BouSaba J, Zheng T, Dilmaghani S, et al. Effect of rapid colonic transit on stool  
540 microbiome and short-chain fatty acids in diarrhoea-predominant irritable bowel  
541 syndrome. *Gut* 2023.
- 542 19. Camilleri M, Carlson P, BouSaba J, et al. Comparison of biochemical, microbial and  
543 mucosal mRNA expression in bile acid diarrhoea and irritable bowel syndrome with  
544 diarrhoea. *Gut* 2023;72:54-65.
- 545 20. Zhao L, Yang W, Chen Y, et al. A Clostridia-rich microbiota enhances bile acid excretion  
546 in diarrhea-predominant irritable bowel syndrome. *J Clin Invest* 2020;130:438-450.
- 547 21. Baumgartner M, Lang M, Holley H, et al. Mucosal Biofilms Are an Endoscopic Feature  
548 of Irritable Bowel Syndrome and Ulcerative Colitis. *Gastroenterology* 2021;161:1245-  
549 1256 e20.
- 550 22. Silva YP, Bernardi A, Frozza RL. The Role of Short-Chain Fatty Acids From Gut  
551 Microbiota in Gut-Brain Communication. *Front Endocrinol (Lausanne)* 2020;11:25.
- 552 23. Ringel-Kulka T, Choi CH, Tamas D, et al. Altered Colonic Bacterial Fermentation as a  
553 Potential Pathophysiological Factor in Irritable Bowel Syndrome. *Am J Gastroenterol*  
554 2015;110:1339-46.
- 555 24. Gargari G, Taverniti V, Gardana C, et al. Fecal Clostridiales distribution and short-chain  
556 fatty acids reflect bowel habits in irritable bowel syndrome. *Environ Microbiol*  
557 2018;20:3201-3213.

- 558 25. Waseem MR, Shin A, Siwiec R, et al. Associations of Fecal Short Chain Fatty Acids  
559 With Colonic Transit, Fecal Bile Acid, and Food Intake in Irritable Bowel Syndrome.  
560 Clin Transl Gastroenterol 2023;14:e00541.
- 561 26. Deehan EC, Yang C, Perez-Munoz ME, et al. Precision Microbiome Modulation with  
562 Discrete Dietary Fiber Structures Directs Short-Chain Fatty Acid Production. Cell Host  
563 Microbe 2020;27:389-404 e6.
- 564 27. Mearin F, Lacy BE, Chang L, et al. Bowel Disorders. Gastroenterology 2016.
- 565 28. Mulligan AA, Luben RN, Bhaniani A, et al. A new tool for converting food frequency  
566 questionnaire data into nutrient and food group values: FETA research methods and  
567 availability. BMJ Open 2014;4:e004503.
- 568 29. Heaton KW, Radvan J, Cripps H, et al. Defecation frequency and timing, and stool form  
569 in the general population: a prospective study. Gut 1992;33:818-24.
- 570 30. Sadik R, Abrahamsson H, Ung KA, Stotzer PO. Accelerated regional bowel transit and  
571 overweight shown in idiopathic bile acid malabsorption. Am J Gastroenterol  
572 2004;99:711-8.
- 573 31. Park J, Kim M, Kang SG, et al. Short-chain fatty acids induce both effector and  
574 regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-  
575 S6K pathway. Mucosal Immunol 2015;8:80-93.
- 576 32. Tagliacozzi D, Mozzi AF, Casetta B, et al. Quantitative analysis of bile acids in human  
577 plasma by liquid chromatography-electrospray tandem mass spectrometry: a simple and  
578 rapid one-step method. Clin Chem Lab Med 2003;41:1633-41.
- 579 33. Vijayvargiya P, Camilleri M, Shin A, Saenger A. Methods for diagnosis of bile acid  
580 malabsorption in clinical practice. Clin Gastroenterol Hepatol 2013;11:1232-9.

- 581 34. Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal  
582 cancer. *Nat Rev Microbiol* 2014;12:661-72.
- 583 35. McMurdie PJ, Holmes S. Phyloseq: a bioconductor package for handling and analysis of  
584 high-throughput phylogenetic sequence data. *Pac Symp Biocomput* 2012:235-46.
- 585 36. Oksanen J, Simpson GL, Blanchet F, et al. *vegan: Community Ecology Package*.  
586 Ordination methods, diversity analysis and other functions for community and vegetation  
587 ecologists. 2.6-4 ed, 2022.
- 588 37. Vieira-Silva S, Falony G, Darzi Y, et al. Species-function relationships shape ecological  
589 properties of the human gut microbiome. *Nat Microbiol* 2016;1:16088.
- 590 38. Vujkovic-Cvijin I, Sklar J, Jiang L, et al. Host variables confound gut microbiota studies  
591 of human disease. *Nature* 2020;587:448-454.
- 592 39. Saad RJ, Rao SS, Koch KL, et al. Do stool form and frequency correlate with whole-gut  
593 and colonic transit? Results from a multicenter study in constipated individuals and  
594 healthy controls. *Am J Gastroenterol* 2010;105:403-11.
- 595 40. Jaruvongvanich V, Patcharatrakul T, Gonlachanvit S. Prediction of Delayed Colonic  
596 Transit Using Bristol Stool Form and Stool Frequency in Eastern Constipated Patients: A  
597 Difference From the West. *J Neurogastroenterol Motil* 2017;23:561-568.
- 598 41. Zhai L, Huang C, Ning Z, et al. *Ruminococcus gnavus* plays a pathogenic role in  
599 diarrhea-predominant irritable bowel syndrome by increasing serotonin biosynthesis. *Cell*  
600 *Host Microbe* 2023;31:33-44 e5.
- 601 42. Yun EJ, Yu S, Park NJ, et al. Metabolic and enzymatic elucidation of cooperative  
602 degradation of red seaweed agarose by two human gut bacteria. *Sci Rep* 2021;11:13955.

- 603 43. Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing species  
604 *Roseburia hominis* and *Faecalibacterium prausnitzii* defines dysbiosis in patients with  
605 ulcerative colitis. *Gut* 2014;63:1275-83.
- 606 44. Quan J, Wu Z, Ye Y, et al. Metagenomic Characterization of Intestinal Regions in Pigs  
607 With Contrasting Feed Efficiency. *Front Microbiol* 2020;11:32.
- 608 45. Armstrong HK, Bording-Jorgensen M, Santer DM, et al. Unfermented beta-fructan Fibers  
609 Fuel Inflammation in Select Inflammatory Bowel Disease Patients. *Gastroenterology*  
610 2023;164:228-240.
- 611 46. Martens EC, Chiang HC, Gordon JI. Mucosal glycan foraging enhances fitness and  
612 transmission of a saccharolytic human gut bacterial symbiont. *Cell Host Microbe*  
613 2008;4:447-57.
- 614 47. Porter NT, Luis AS, Martens EC. *Bacteroides thetaiotaomicron*. *Trends Microbiol*  
615 2018;26:966-967.
- 616 48. Shetty SA, Boeren S, Bui TPN, et al. Unravelling lactate-acetate and sugar conversion  
617 into butyrate by intestinal *Anaerobutyricum* and *Anaerostipes* species by comparative  
618 proteogenomics. *Environ Microbiol* 2020;22:4863-4875.
- 619 49. Henke MT, Kenny DJ, Cassilly CD, et al. *Ruminococcus gnavus*, a member of the human  
620 gut microbiome associated with Crohn's disease, produces an inflammatory  
621 polysaccharide. *Proc Natl Acad Sci U S A* 2019;116:12672-12677.
- 622 50. Bell A, Brunt J, Crost E, et al. Elucidation of a sialic acid metabolism pathway in mucus-  
623 foraging *Ruminococcus gnavus* unravels mechanisms of bacterial adaptation to the gut.  
624 *Nat Microbiol* 2019;4:2393-2404.

- 625 51. Shin A, Xu H, Imperiale TF. Associations of chronic diarrhoea with non-alcoholic fatty  
626 liver disease and obesity-related disorders among US adults. *BMJ Open Gastroenterol*  
627 2019;6:e000322.
- 628 52. Hehemann JH, Correc G, Barbeyron T, et al. Transfer of carbohydrate-active enzymes  
629 from marine bacteria to Japanese gut microbiota. *Nature* 2010;464:908-12.
- 630 53. Hehemann JH, Kelly AG, Pudlo NA, et al. Bacteria of the human gut microbiome  
631 catabolize red seaweed glycans with carbohydrate-active enzyme updates from extrinsic  
632 microbes. *Proc Natl Acad Sci U S A* 2012;109:19786-91.
- 633 54. De Filippis F, Pasolli E, Tett A, et al. Distinct Genetic and Functional Traits of Human  
634 Intestinal *Prevotella copri* Strains Are Associated with Different Habitual Diets. *Cell*  
635 *Host Microbe* 2019;25:444-453 e3.
- 636 55. Derrien M, Turrone F, Ventura M, van Sinderen D. Insights into endogenous  
637 *Bifidobacterium* species in the human gut microbiota during adulthood. *Trends Microbiol*  
638 2022;30:940-947.
- 639 56. Jacobs JP, Lagishetty V, Hauer MC, et al. Multi-omics profiles of the intestinal  
640 microbiome in irritable bowel syndrome and its bowel habit subtypes. *Microbiome*  
641 2023;11:5.
- 642 57. Klem F, Wadhwa A, Prokop LJ, et al. Prevalence, Risk Factors, and Outcomes of  
643 Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-  
644 analysis. *Gastroenterology* 2017;152:1042-1054 e1.
- 645 58. Breen-Lyles M, Decuir M, Byale A, et al. Impact of Rome IV criteria on the prevalence  
646 of post-infection irritable bowel syndrome. *Neurogastroenterol Motil* 2023;35:e14532.

- 647 59. Pimentel M, Chang C, Chua KS, et al. Antibiotic treatment of constipation-predominant  
648 irritable bowel syndrome. *Dig Dis Sci* 2014;59:1278-85.
- 649 60. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable  
650 bowel syndrome without constipation. *N Engl J Med* 2011;364:22-32.
- 651 61. Lembo A, Sultan S, Chang L, et al. AGA Clinical Practice Guideline on the  
652 Pharmacological Management of Irritable Bowel Syndrome With Diarrhea.  
653 *Gastroenterology* 2022;163:137-151.
- 654 62. Vacca M, Celano G, Calabrese FM, et al. The Controversial Role of Human Gut  
655 Lachnospiraceae. *Microorganisms* 2020;8.
- 656 63. Wang Z, Bai Y, Pi Y, et al. Xylan alleviates dietary fiber deprivation-induced dysbiosis  
657 by selectively promoting *Bifidobacterium pseudocatenulatum* in pigs. *Microbiome*  
658 2021;9:227.
- 659 64. Gobert AP, Sagrestani G, Delmas E, et al. The human intestinal microbiota of  
660 constipated-predominant irritable bowel syndrome patients exhibits anti-inflammatory  
661 properties. *Sci Rep* 2016;6:39399.
- 662 65. Choo C, Mahurkar-Joshi S, Dong TS, et al. Colonic mucosal microbiota is associated  
663 with bowel habit subtype and abdominal pain in patients with irritable bowel syndrome.  
664 *Am J Physiol Gastrointest Liver Physiol* 2022;323:G134-G143.
- 665 66. Louis P, Flint HJ. Formation of propionate and butyrate by the human colonic  
666 microbiota. *Environ Microbiol* 2017;19:29-41.
- 667 67. Jiang L, Shang M, Yu S, et al. A high-fiber diet synergizes with *Prevotella copri* and  
668 exacerbates rheumatoid arthritis. *Cell Mol Immunol* 2022;19:1414-1424.

- 669 68. Belenguer A, Duncan SH, Calder AG, et al. Two routes of metabolic cross-feeding  
670 between *Bifidobacterium adolescentis* and butyrate-producing anaerobes from the human  
671 gut. *Appl Environ Microbiol* 2006;72:3593-9.
- 672 69. Duranti S, Ruiz L, Lugli GA, et al. *Bifidobacterium adolescentis* as a key member of the  
673 human gut microbiota in the production of GABA. *Sci Rep* 2020;10:14112.
- 674 70. Pichler MJ, Yamada C, Shuoker B, et al. Butyrate producing colonic Clostridiales  
675 metabolise human milk oligosaccharides and cross feed on mucin via conserved  
676 pathways. *Nat Commun* 2020;11:3285.
- 677 71. Wijdeveld M, Schranter A, Hagemeijer A, et al. Intestinal acetate and butyrate  
678 availability is associated with glucose metabolism in healthy individuals. *iScience*  
679 2023;26:108478.
- 680 72. Carco C, Young W, Geary RB, et al. Increasing Evidence That Irritable Bowel  
681 Syndrome and Functional Gastrointestinal Disorders Have a Microbial Pathogenesis.  
682 *Front Cell Infect Microbiol* 2020;10:468.
- 683 73. Mulder D, Jakobi B, Shi Y, et al. Gut microbiota composition links to variation in  
684 functional domains across psychiatric disorders. *Brain Behav Immun* 2024;120:275-287.
- 685 74. Yu L, Chen X, Bai X, et al. Microbiota Alters and Its Correlation with Molecular  
686 Regulation Underlying Depression in PCOS Patients. *Mol Neurobiol* 2023.
- 687 75. Xiao L, Liu S, Wu Y, et al. The interactions between host genome and gut microbiome  
688 increase the risk of psychiatric disorders: Mendelian randomization and biological  
689 annotation. *Brain Behav Immun* 2023;113:389-400.



- 690 76. Onate FP, Chamignon C, Burz SD, et al. Adlercreutzia equolifaciens Is an Anti-  
691 Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of  
692 Patients with Metabolic Liver Disease. *Int J Mol Sci* 2023;24.
- 693 77. Calderon G, Patel C, Camilleri M, et al. Associations of Habitual Dietary Intake With  
694 Fecal Short-Chain Fatty Acids and Bowel Functions in Irritable Bowel Syndrome. *J Clin*  
695 *Gastroenterol* 2022;56:234-242.
- 696
- 697
- 698
- 699

700 **Table 1:** Clinical Characteristics of Patients with Irritable Bowel Syndrome (IBS) and Controls

<i>Data show mean (standard deviation [SD]) except where specified</i>	<b>Controls (n=17)</b>	<b>IBS-C (n=15)</b>	<b>IBS- D (n=26)</b>
<b>Age (years)</b>	31.7 (13.6)	34.3 (10.5)	38.7 (15.3)
<b>Women, n (%)</b>	12 (71%)	13 (87%)	18 (70%)
<b>BMI, kg/m<sup>2</sup></b>	26.3 (5.9)	25.3 (5.2)	26.7 (9.4)
<b>White, n (%)</b>	9 (53%)	10 (67%)	23 (88%)
<b>Baseline dietary intake*</b>			
Energy (kcal)	1946.8 (1025.7)	2028.4 (1717.3)	1514.1 (557.4)
Total carbohydrates (g)	219.4 (155.6)	191.1 (153.7)	160.1 (62.9)
Starch (g)	104.7 (54.9)	107.9 (110.9)	87.7 (46.9)
Protein (g)	100.9 (47.1)	96.8 (75.3)	75.1 (23.4)
Fat (g)	77.6 (34.7)	99.6 (101.9)	63.8 (30.3)
Fiber (g)	17.9 (20.9)	14.3 (10.0)	11.6 (4.1)

701 *Group comparisons were conducted using the ANOVA F- and Fisher exact tests. IBS-C, IBS with*  
 702 *constipation; IBS-D, IBS with diarrhea; \*Diet data missing for two participants with IBS-C and*  
 703 *four participants with IBS-D*

704

705 **Table 2:** Quantitative Traits in Patients with Irritable Bowel Syndrome (IBS) and Controls

<i>Data show median (interquartile range)</i>	<b>Controls (n=17)</b>	<b>IBS-C (n=15)</b>	<b>IBS- D (n=26)</b>
<b>Total stool bile acids (μmol/48h)*#</b> <sup>\$</sup>	342 (130-640)	190 (110-449)	607 (447-1235)
<b>Primary stool bile acids (%)</b>	2.1 (0.8-9.1)	1.8 (0.8-2.4)	3.1 (0.8-12.4)
<b>Total stool SCFA (μg/mg)</b> <sup>@**</sup>	9.8 (4.5-13.8)	11.6 (7.7-20.0)	14.3 (10.0-20.8)
<b>Stool acetate</b> <sup>@*</sup>	6.3 (3.3-8.5)	7.1 (5.3-12.8)	9.4 (5.9-14.1)
<b>Stool propionate</b>	1.7 (0.8-2.4)	2.2 (1.5-2.9)	2.4 (1.6-4.0)
<b>Stool butyrate</b>	1.2 (0.5-2.4)	2.2 (1.0-3.7)	1.9 (1.0-3.6)
<b>Acetate to butyrate ratio</b>	5.0 (3.3-6.7)	3.7 (2.7-4.9)	4.5 (3.3-6.7)
<b>Total colonic transit time (CTT), days</b>	1.4 (0.2-2.5)	1.5 (1.0-2.1)	0.9 (0.5-1.5)
<b>Right CTT, days</b>	0.6 (0.3-0.6)	0.4 (0.2-0.8)	0.4 (0.2-0.6)
<b>Transverse CTT, days</b>	0.1 (0-0.4)	0.3 (0-0.8)	0.1 (0-0.3)
<b>Left CTT, days**#</b>	0.5 (0.3-1.9)	0.5 (0.2-1.1)	0.3 (0.1-0.5)

706 *IBS-C=IBS with constipation; IBS-D=IBS with diarrhea; SCFA=short chain fatty acids.*  
 707 *Comparisons across groups were conducted using the Kruskal-Wallis test. For traits showing*  
 708 *significant differences (\*p<0.05; \*\*p=0.05), pairwise comparisons were conducted with Dunn's*  
 709 *test, applying Bonferroni correction for multiple tests. #p<0.05 for Controls vs. IBS-D; \$p=0.001*  
 710 *for IBS-C vs. IBS-D; all other pairwise comparisons were non-significant (e.g., IBS-C vs.*  
 711 *controls); @\* p<0.05 for Controls vs. IBS. @\*\* p=0.05 for Controls vs. IBS*  
 712

713 **FIGURE LEGENDS**

714 **Figure 1:** Consort Flow Diagram

715 **Figure 2:** Stool Short Chain Fatty Acid Concentrations in Healthy Volunteers and Participants  
716 with Irritable Bowel Syndrome (IBS). *Histograms are shown for total short chain fatty acids,*  
717 *acetate, butyrate, propionate, and acetate to butyrate ratios within clinical groups including*  
718 *healthy volunteers (HV), IBS with constipation (IBS-C), and IBS with diarrhea (IBS-D). Groups*  
719 *are denoted by color (HV = red, IBS-C = green, IBS-D = blue).*

720 **Figure 2:** Stool Bile Acids in Healthy Volunteers and Participants with Irritable Bowel  
721 Syndrome (IBS). *Histograms are shown for % primary bile acids (bile.acids) and total bile acids*  
722 *within clinical groups including healthy volunteers (HV), IBS with constipation (IBS-C), and IBS*  
723 *with diarrhea (IBS-D). Groups are denoted by color (HV = red, IBS-C = green, IBS-D = blue).*

724 **Figure 4:** Bacterial Taxa with Differential Abundance of  $\geq 3$ -fold Between Groups. *Data show*  
725 *mean percent abundances (standard deviation) of significantly different bacterial taxa with  $\geq 3$ -*  
726 *fold differences in pairwise comparisons of clinical cohorts.*


727 **Figures 5:** Correlations of bacterial taxa with short chain fatty acids (SCFA) based on partial  
728 canonical correspondence analysis. *Panels show associations between bacterial taxa and specific*  
729 *SCFA([a] acetate, [b] butyrate, [c] propionate, and [d] and acetate to butyrate ratio) within*  
730 *cohorts. The strength of the correlation is represented projections  $>0.5$  with purple indicating*  
731 *negative correlations and red indicating positive correlations.*

732 **Figure 6:** Variations in Microbial Substrate Utilization in Healthy Volunteers and Participants  
733 with IBS. *Figure shows significant differences in functional potential for carbohydrate*  
734 *degradation, short chain fatty acid production or metabolism, and mucin degradation across*


735 *clinical groups in representative subset selected by stool form characteristics. Groups are*  
736 *denoted by color (HV = blue, IBS-C = red, IBS-D = gray).*

737


738




Histograms with Density Curves by Cohort




Histograms with Density Curves by Cohort




Histograms with Density Curves by Cohort




Histograms with Density Curves by Cohort



Histograms with Density Curves by Cohort




### Histograms with Density Curves by Cohort



Type of IBS

- HV
- IBS - C
- IBS - D

### Histograms with Density Curves by Cohort



Type of IBS

- HV
- IBS - C
- IBS - D



Mean percent abundances (standard deviation) of significantly different high abundant bacterial taxa in pairwise comparisons

Taxa	Controls	IBS-C	IBS-D	IBS-C vs. Controls (p-value)	IBS-D vs. Controls (p-value)	IBS-C vs. IBS-D (p-value)
<i>Akkermansia muciniphila</i>	0.294 (±1.022)	1.890 (±3.138)	1.241 (±2.676)	0.029	ns	ns
<i>Bifidobacterium pseudocatenulatum</i>	0.064 (±0.167)	0.041 (±0.154)	1.510 (±6.706)	ns	0.034	0.006
<i>Blautia</i> sp. CAG:257*	0.016 (±0.034)	0.043 (±0.122)	0.121 (±0.220)	ns	0.03	ns
<i>Clostridium</i> sp. CAG:58*	0.013 (±0.022)	0.174 (±0.201)	0.253 (±0.546)	0.004	0.025	ns
<i>Dorea</i> sp. CAG:317*	0.008 (±0.025)	0.006 (±0.025)	0.132 (±0.306)	ns	0.03	0.011
<i>Firmicutes bacterium</i> CAG:110	0.273 (±0.519)	0.030 (±0.096)	0.037 (±0.110)	0.047	ns	ns
<i>Firmicutes bacterium</i> CAG:83*	1.046 (±3.048)	0.135 (±0.185)	0.551 (±1.845)	ns	0.002	0.038
<i>Monoglobus pectinilyticus</i> **	0.164 (±0.540)	0.198 (±0.303)	0.081 (±0.374)	0.028	ns	0.008
<i>Prevotella copri</i>	2.037 (±5.027)	8.401 (±19.932)	3.986 (±12.817)	0.049	ns	ns
<i>Proteobacteria bacterium</i> CAG:139*	0.020 (±0.036)	0.364 (±0.810)	0.635 (±1.512)	ns	0.008	ns
<i>Ruminococcus torques</i>	3.299 (±5.879)	0.755 (±1.570)	0.971 (±1.683)	ns	0.044	ns
<i>Streptococcus salivarius</i>	0.092 (±0.230)	0.121 (±0.177)	0.200 (±0.343)	0.021	ns	ns

\*bacterial species that were significantly different in overall comparisons; \*\* differential increase in *M. pectinilyticus* abundance in IBS-C vs. controls or IBS-D <3-fold; color scheme represents relative abundance with higher values noted in darker blue

